Overview: t(1;19) TCF3-PBX1 Qualitative PCR TestIntroduction: The t(1;19) TCF3-PBX1 Qualitative PCR Test detects TCF3-PBX1 translocation to diagnose leukemia, causing fatigue or bruising. Following 2023 ASH guidelines, it uses PCR for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected leukemia.
Other Names: TCF3-PBX1 PCR Assay, Leukemia Translocation Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: TCF3-PBX1 testing began in the 1990s with leukemia research. PCR methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects TCF3-PBX1 translocation to diagnose leukemia, guides treatment, and evaluates patients with fatigue or bruising.
Test Parameters: 1. TCF3-PBX1 Translocation
Pretest Condition: No fasting required. Collect whole blood, bone marrow, or saliva. Report history of fatigue, bruising, or leukemia symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Bone Marrow (EDTA, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document fatigue, bruising, or history of leukemia. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, leukemia implications, and risks of sample collection.
Procedural Considerations: Uses qualitative PCR to detect TCF3-PBX1 translocation. Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for leukemia diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Sample quality impacts specificity.
Clinical Significance: Positive translocation confirms leukemia, guiding chemotherapy or targeted therapy. Negative results may require other cytogenetic testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: FISH, karyotyping, or bone marrow biopsy to confirm leukemia diagnosis.
Test Limitations: Specific to TCF3-PBX1; other translocations may be missed. Clinical correlation is needed.
References: ASH Leukemia Guidelines, 2023; Blood, Hunger SP, 2022.
